bioRxivCancer BiologyPreprint
Decoding Plasticity Regulators and Transition Trajectories in Glioblastoma with Single-cell Multiomics
Manu SaraswatiD, Laura Rueda-GensiniiD, Elisa HeinzelmanniD, Tannia GraciaiD, Fani MemiiD, Grant de Jong, Jannes StraubiD, Cedar SchlooiD, Dirk C. HoffmanniD, Erik JungiD, Tim Kindinger, Bettina WeigeliD, Bryce LimiD, Sophie Weil, Oliver Gould, Richard James MairiD, Katharina Mikulik, Martin Rohbeck, Wolfgang WickiD, Frank WinkleriD, Omer Ali BayraktariD, Oliver StegleiD, Moritz MalliD
Abstract
Glioblastoma (GB) is one of the most lethal human cancers, marked by profound intratumoral heterogeneity and near-universal treatment resistance. Cellular plasticity, the capacity of cancer cells to transition between phenotypic states, drives GB progression and resistance. However, the regulatory logic that permits or restricts specific state transitions remains poorly understood. Here, we integrated single-nucleus RNA and chromatin accessibility multi-ome profiles from over one million cells across primary IDH-wildtype GBs and developed scDORI, a scalable deep-learning framework to infer enhancer-driven gene regulatory networks (eGRNs) at single-cell resolution. Our analysis revealed a structured hierarchy of GB cell states governed by distinct regulatory programs, with marked variability in epigenetic plasticity that enables or constrains transitions. Neuronal-like tumor cells emerge as a low plasticity state that deploys active repression, in contrast to more permissive progenitor-like and astrocytic states. We identified the neuronal-like state-specific repressor MYT1L as a key regulator that silences master transcription factors of alternative states. MYT1L gain-of-function in patient-derived GB cells reduced chromatin accessibility, induced neuronal-like identity, and restricted proliferation and invasion in vivo, whereas loss-of-function reactivated plasticity and accelerated malignant features. Our findings delineate the epigenetic architecture and associated transcriptional master regulators that shape GB state trajectories, and establish safeguard repressors such as MYT1L as potential therapeutic targets to constrain malignant plasticity.
- organism: human
- assay: scRNA-seq
- assay: ATAC-seq
- assay: multiome
- research focus: chromatin & epigenetic regulation
- research focus: cell type annotation
- research focus: gene regulatory network inference
- approach: deep learning
- Citations
- 10
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Spatial epigenomic niches underlie glioblastoma cell state plasticity
Sam Kint, Subhi Talal Younes, … Marco Gallo·bioRxiv·May 9, 2025
- Targeting Glioblastoma Cell State Plasticity for Enhanced Therapeutic Efficacy
Stéfano M. Cirigliano, Richa Singhania, … Howard Alan Fine·bioRxiv·Sep 8, 2025
- A single-cell based precision medicine approach using glioblastoma patient-specific models
James Hugh Park, Abdullah Hamid Feroze, … Anoop P. Patel·npj Precision OncologyPeer-reviewed·Aug 8, 2022
- A novel ILK/STAT3 pathway controls plasticity in a neural stem cell model of glioblastoma.
A. E. P. Loftus, M. S. Romano, … M. C. Frame·bioRxiv·Jul 19, 2023
- Network Analyses of Brain Tumor Patients' Multiomic Data Reveals Pharmacological Opportunities to Alter Cell State Transitions
Brandon Bumbaca, Jonah R. Huggins, … James M. Gallo·npj Systems Biology and ApplicationsPeer-reviewed·Feb 1, 2025
- Futile wound healing drives mesenchymal-like cell phenotypes in human glioblastoma
A. Mossi Albiach, J. Janusauskas, … S. Linnarsson·bioRxiv·Sep 1, 2023